Lupin Wins Tentative US FDA Approval for a Liquid Version of Apixaban, Yet the Stock Slips With the Market
- September 28, 2026
- Posted by: Harsh Piplani
- Category: News
Lupin Rs 2,066.70, down 1.21% (28 Sep, 11 AM). 52-week range Rs 1,900 to 2,529.50. RSI 43.1. Q1 FY27 profit around Rs 1,417 crore. P/E 17.22 against industry 38.42.
Quick Answer
The Lupin share price was Rs 2,066.70 at 11 AM on 28 September 2026, down 1.21 percent, even after the company received tentative US FDA approval for Apixaban Oral Suspension 1.25 mg/mL. The approval is tentative, so Lupin cannot sell the product in the United States until the FDA grants final approval. The stock trades below its 20-day average of Rs 2,106.58 while the Sensex is down more than 1.3 percent, so the news has not yet shown up in the price. Once final approval arrives, Lupin plans to manufacture the product at its Somerset facility in New Jersey.
Lupin Limited said on Monday that the US Food and Drug Administration has tentatively approved its New Drug Application for Apixaban Oral Suspension 1.25 mg/mL under the 505(b)(2) pathway. Apixaban is the active ingredient in Bristol Myers Squibb’s blood thinner Eliquis, and Lupin’s version is an oral liquid for adults on anticoagulation therapy who find tablets hard to swallow.
Click Here – Get Free Investment Predictions
The market did not reward the announcement. Lupin traded between Rs 2,062.80 and Rs 2,098.60 by 11 AM against a previous close of Rs 2,092. This article explains what the approval means, what it does not, and where the Lupin share price stands on the charts and on valuation.
Why Is the Lupin Share Price Down on Good News?
The Lupin share price is down because the whole market is down, and a tentative approval carries no immediate revenue. The Sensex was down 1.33 percent at 72,912.95 at 10:50 AM, and large caps across sectors were under pressure from higher oil prices and rate-hike worries.
A tentative approval means the FDA has found the application acceptable, but the right to launch depends on final approval, which in turn depends on conditions such as patent and exclusivity timelines. The disclosures reviewed do not give a launch date or a revenue estimate for the product.
Investors also know Lupin has been here before. It received tentative approval for generic apixaban tablets in December 2018, and the new oral suspension is a separate application with a different formulation and a different route to market.
What the Apixaban Oral Suspension Adds for Lupin
The liquid formulation gives Lupin a differentiated product in a drug class where most patients take tablets. Chief Executive Vinita Gupta said the approval reflects the company’s focus on differentiated medicines that address patient needs and widens administration options for the therapy.
| Item | Detail |
|---|---|
| Product | Apixaban Oral Suspension 1.25 mg/mL |
| Regulatory route | New Drug Application, 505(b)(2) pathway |
| Status | Tentative approval from the US FDA |
| Reference active ingredient | Apixaban, found in Eliquis (Bristol Myers Squibb) |
| Planned manufacturing site | Somerset, New Jersey, after final approval |
| Announced | 28 September 2026 |
Making the product in the United States could reduce the supply-chain and inspection risks that sometimes affect imports, and it fits Lupin’s push into complex formulations. The commercial value, and any lift to the Lupin share price, will only be clear once final approval and a launch timeline are announced.
Also read – Nifty Slips Below 23,000 as Sensex Tests Its Support Zone: What Drove the Selloff and What to Watch
Lupin Share Price Today: Numbers and Technical Levels
| Metric | Value (28 Sep, 11 AM) |
|---|---|
| Lupin share price (Lupin Ltd) | Rs 2,066.70 (down 1.21%) |
| Day range | Rs 2,062.80 to Rs 2,098.60 |
| Previous close | Rs 2,092.00 |
| 52-week high / low | Rs 2,529.50 / Rs 1,900.00 |
| RSI (14-day) | 43.1 |
| MACD vs signal line | -38.19 vs -45.84 |
| SuperTrend | Bearish, resistance at Rs 2,164.08 |
| 20-day average | Rs 2,106.58 |
| Market cap (Friday close) | Rs 95,574 crore |
| P/E vs industry P/E | 17.22 vs 38.42 |
| Return on equity / debt to equity | 23.76% / 0.29 |
The Lupin share price sits 18.3 percent below its 52-week high of Rs 2,529.50 and 8.8 percent above its 52-week low of Rs 1,900. The MACD line is still below zero but has moved above its signal line, which points to easing downside momentum, while the SuperTrend indicator stays bearish with resistance at Rs 2,164.08. A close above the 20-day average of Rs 2,106.58 would be the first sign of a shift.
Check Live Prices, RSI and Fundamentals on the Univest Screener
Quarterly Numbers Behind the Lupin Share Price
Lupin’s first-quarter FY27 net profit was about Rs 1,417 crore, up 16 percent from Rs 1,221 crore a year earlier, and revenue from operations crossed Rs 8,000 crore for the first time. US sales rose 42.9 percent to $366 million and made up 42 percent of global sales, while India sales grew 13.9 percent.
The risk is that the quarter may be a high-water mark. Management guided a full-year EBITDA margin of around 25 percent, below the roughly 30 percent of Q1, and high single-digit revenue growth for FY27, which implies a slower pace than the 33 percent seen in the quarter. A weaker US contribution from competition on key products would weigh on the Lupin share price.
Balance sheet strength helps the Lupin share price hold its floor. Debt to equity is 0.29, return on equity is 23.76 percent and the company reported a net cash position at the end of June, with net debt to equity of -0.12.
Buy, Hold or Sell: What Could Move the Lupin Share Price Next
Three things decide the next leg for the Lupin share price: the timing of final FDA approval, the pace of US launches, and the Q2 FY27 results due by 14 November under the 45-day rule. A P/E of 17.22 against an industry figure of 38.42 leaves room for a re-rating if earnings hold, but the discount also reflects US pricing pressure.
Anyone considering whether to buy Lupin shares should treat the tentative approval as a small positive, not a catalyst that changes the earnings outlook on its own. Position sizing and a stop-loss matter more than the headline for the Lupin share price.
Also read – Trump Rejects Iran’s Peace Proposal: Oil Climbs, the Dollar Firms and Gold Falls as Rate-Hike Bets Build
Download the Univest iOS App or Univest Android App to track Lupin’s live price and get alerts on FDA and corporate announcements.
Conclusion
The Lupin share price of Rs 2,066.70 reflects a weak market more than the approval news, since a tentative FDA nod brings no sales until final approval and a launch. Strong Q1 profit and a low P/E are supports, while guided margin normalisation and US competition are the risks. Investors weighing whether to buy Lupin should watch the Rs 2,106 to 2,164 zone, follow stop-loss levels and consult a SEBI-registered adviser before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Lupin share price today?
Ans. The Lupin share price was Rs 2,066.70 at 11 AM on 28 September 2026, down 1.21 percent from the previous close of Rs 2,092. The day range so far is Rs 2,062.80 to Rs 2,098.60.
Why is the Lupin share price falling today despite the FDA approval?
Ans. The Lupin share price is under pressure because the market is weak, with the Sensex down about 1.3 percent, and a tentative approval does not bring immediate sales. Investors are waiting for final approval and a launch timeline.
What did the US FDA approve for Lupin?
Ans. The FDA tentatively approved Lupin’s New Drug Application for Apixaban Oral Suspension 1.25 mg/mL through the 505(b)(2) pathway. It is an oral liquid form of apixaban for adults who have difficulty swallowing tablets.
Does tentative approval allow Lupin to sell the drug?
Ans. No. Tentative approval means the application meets requirements, but the product cannot be marketed in the United States until the FDA grants final approval.
Is the Lupin share price near its 52-week low?
Ans. The Lupin share price is 8.8 percent above the 52-week low of Rs 1,900 and 18.3 percent below the 52-week high of Rs 2,529.50, so it sits in the lower part of its yearly range.
What are the key technical levels for the Lupin share price?
Ans. The key levels for the Lupin share price are SuperTrend resistance at Rs 2,164.08 and the 20-day average is Rs 2,106.58. The 52-week low of Rs 1,900 is the major support, and the RSI reading is 43.1.
What were Lupin’s Q1 FY27 results?
Ans. Net profit was about Rs 1,417 crore, up 16 percent, and revenue from operations crossed Rs 8,000 crore. US sales rose 42.9 percent to $366 million.
Is the Lupin share price a buy after the FDA news?
Ans. The approval is a modest positive for the Lupin share price, but it is tentative and guidance points to lower margins later in FY27. Investors should check their risk appetite, use a stop-loss and consult a SEBI-registered adviser.
